{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:35Z","timestamp":1792785035139,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["64-143"],"award-info":[{"award-number":["64-143"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Siriraj Core Research Facility (SiCRF) and Strategic Project Grant"},{"name":"Siriraj Chalermphrakiat Grant"},{"name":"the Thanapat Fund","award":["D003752"],"award-info":[{"award-number":["D003752"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95834-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:30:24Z","timestamp":1743787824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive germline and somatic profiling of high-risk Thai breast cancer via next-generation sequencing"],"prefix":"10.1038","volume":"15","author":[{"given":"Kornyok","family":"Kamdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkapong","family":"Roothumnong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanna","family":"Thongnoppakhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittiya","family":"Korphaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panee","family":"Nakthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peerawat","family":"Dungort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutima","family":"Meesamarnpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supakit","family":"Wiboontanasarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warisara","family":"Tansa-nga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittiporn","family":"Punuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khontawan","family":"Pongsuktavorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warunya","family":"Tititumjariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chittapat","family":"Lertbussarakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantanee","family":"Wattanarangsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiraporn","family":"Sritun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Numpueng","family":"Ridchuayrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manop","family":"Pithukpakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoom","family":"Suktitipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"95834_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"95834_CR2","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.18632\/aging.202502","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Global incidence and mortality of breast cancer: a trend analysis. Aging (Albany NY). 13, 5748\u20135803 (2021).","journal-title":"Aging (Albany NY)"},{"key":"95834_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N Engl. J. Med. 384, 440\u2013451 (2021).","journal-title":"N Engl. J. Med."},{"key":"95834_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch, F. J. et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 3, 1190\u20131196 (2017).","journal-title":"JAMA Oncol."},{"key":"95834_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch, P. D. et al. Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle?? J. Clin. Oncol. 37, 453\u2013460 (2019).","journal-title":"J. Clin. Oncol."},{"key":"95834_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31601","volume":"144","author":"JY Li","year":"2019","unstructured":"Li, J. Y. et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int. J. Cancer. 144, 281\u2013289 (2019).","journal-title":"Int. J. Cancer"},{"key":"95834_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4143\/crt.2019.559","volume":"52","author":"HC Shin","year":"2020","unstructured":"Shin, H. C. et al. Detection of germline mutations in breast cancer patients with clinical features of hereditary cancer syndrome using a Multi-Gene panel test. Cancer Res. Treat. 52, 697\u2013713 (2020).","journal-title":"Cancer Res. Treat."},{"key":"95834_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"95834_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"95834_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127\u20131133 (2013).","journal-title":"Nat. Genet."},{"key":"95834_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"95834_CR12","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2433 breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).","journal-title":"Nat. Commun."},{"key":"95834_CR13","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","volume":"11","author":"GT Lang","year":"2020","unstructured":"Lang, G. T. et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat. Commun. 11, 5679 (2020).","journal-title":"Nat. Commun."},{"key":"95834_CR14","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1038\/s41467-020-20173-5","volume":"11","author":"JW Pan","year":"2020","unstructured":"Pan, J. W. et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat. Commun. 11, 6433 (2020).","journal-title":"Nat. Commun."},{"key":"95834_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41467-018-04129-4","volume":"9","author":"Z Kan","year":"2018","unstructured":"Kan, Z. et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat. Commun. 9, 1725 (2018).","journal-title":"Nat. Commun."},{"key":"95834_CR16","first-page":"100076","volume":"3","author":"B Zhu","year":"2022","unstructured":"Zhu, B. et al. Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. HGG Adv. 3, 100076 (2022).","journal-title":"HGG Adv."},{"key":"95834_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jmcb\/mjz067","volume":"11","author":"J Bargonetti","year":"2019","unstructured":"Bargonetti, J. & Prives, C. Gain-of-function mutant p53: history and speculation. J. Mol. Cell. Biol. 11, 605\u2013609 (2019).","journal-title":"J. Mol. Cell. Biol."},{"key":"95834_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/bcr3605","volume":"16","author":"D Zardavas","year":"2014","unstructured":"Zardavas, D., Phillips, W. A. & Loi, S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res. 16, 201 (2014).","journal-title":"Breast Cancer Res."},{"key":"95834_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321\u2013337e310 (2018).","journal-title":"Cell"},{"key":"95834_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"95834_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","volume":"9","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell. Discov. 9, 125 (2023).","journal-title":"Cell. Discov"},{"key":"95834_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung, N. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121, 25\u201333 (2015).","journal-title":"Cancer"},{"key":"95834_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41525-024-00400-4","volume":"9","author":"C Kansuttiviwat","year":"2024","unstructured":"Kansuttiviwat, C. et al. Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand. NPJ Genom Med. 9, 9 (2024).","journal-title":"NPJ Genom Med."},{"key":"95834_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cas.14242","volume":"111","author":"D Shao","year":"2020","unstructured":"Shao, D. et al. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. Cancer Sci. 111, 647\u2013657 (2020).","journal-title":"Cancer Sci."},{"key":"95834_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13053-017-0085-6","volume":"16","author":"C Heramb","year":"2018","unstructured":"Heramb, C. et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. Hered Cancer Clin. Pract. 16, 3 (2018).","journal-title":"Hered Cancer Clin. Pract."},{"key":"95834_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00031","volume":"1","author":"WD den Brok","year":"2017","unstructured":"den Brok, W. D. et al. Homologous recombination deficiency in breast cancer: A clinical review. JCO Precis Oncol. 1, 1\u201313 (2017).","journal-title":"JCO Precis Oncol."},{"key":"95834_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ygyno.2020.09.029","volume":"159","author":"EH Stover","year":"2020","unstructured":"Stover, E. H., Fuh, K., Konstantinopoulos, P. A., Matulonis, U. A. & Liu, J. F. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol. Oncol. 159, 887\u2013898 (2020).","journal-title":"Gynecol. Oncol."},{"key":"95834_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"MS Lawrence","year":"2015","unstructured":"Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576\u2013582 (2015).","journal-title":"Nature"},{"key":"95834_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41523-020-00195-4","volume":"6","author":"F Pareja","year":"2020","unstructured":"Pareja, F. et al. The genomic landscape of metastatic histologic special types of invasive breast cancer. NPJ Breast Cancer. 6, 53 (2020).","journal-title":"NPJ Breast Cancer"},{"key":"95834_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell. 34, 893\u2013905e898 (2018).","journal-title":"Cancer Cell."},{"key":"95834_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10549-019-05142-x","volume":"175","author":"SX Yang","year":"2019","unstructured":"Yang, S. X. & Polley, E. C. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. Breast Cancer Res. Treat. 175, 287\u2013295 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"95834_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase Inhibition. Nature 486, 353\u2013360 (2012).","journal-title":"Nature"},{"key":"95834_CR33","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1038\/s41467-018-07407-3","volume":"9","author":"OL Griffith","year":"2018","unstructured":"Griffith, O. L. et al. Author correction: The prognostic effects of somatic mutations in ER-positive breast cancer. Nat. Commun. 9, 4850 (2018).","journal-title":"Nat. Commun."},{"key":"95834_CR34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1186\/s12885-022-10196-0","volume":"22","author":"C Ditsatham","year":"2022","unstructured":"Ditsatham, C. et al. Breast cancer subtypes in Northern Thailand and barriers to satisfactory survival outcomes. BMC cancer. 22, 1147 (2022).","journal-title":"BMC cancer"},{"key":"95834_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.trecan.2021.04.009","volume":"7","author":"G El Tekle","year":"2021","unstructured":"El Tekle, G. et al. Co-occurrence and mutual exclusivity: What cross-cancer mutation patterns can tell Us. Trends Cancer. 7, 823\u2013836 (2021).","journal-title":"Trends Cancer"},{"key":"95834_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ijms14010088","volume":"14","author":"JC Chen","year":"2013","unstructured":"Chen, J. C., Chang, Y. W., Hong, C. C., Yu, Y. H. & Su, J. L. The role of the VEGF-C\/VEGFRs axis in tumor progression and therapy. Int. J. Mol. Sci. 14, 88\u2013107 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"95834_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/genes12101611","volume":"12","author":"N Liu","year":"2021","unstructured":"Liu, N. & Gao, M. FLT4 mutations are associated with segmental lymphatic dysfunction and initial lymphatic aplasia in patients with Milroy disease. Genes (Basel). 12, 1611 (2021).","journal-title":"Genes (Basel)"},{"key":"95834_CR38","doi-asserted-by":"crossref","unstructured":"Gu, Y. et al. Case report: unique FLT4 variants associated with differential response to anlotinib in angiosarcoma. Front. Oncol. 12, (2022).","DOI":"10.3389\/fonc.2022.1027696"},{"key":"95834_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.7150\/thno.81847","volume":"13","author":"C Marvalim","year":"2023","unstructured":"Marvalim, C., Datta, A. & Lee, S. C. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics 13, 1421\u20131442 (2023).","journal-title":"Theranostics"},{"key":"95834_CR40","doi-asserted-by":"publisher","first-page":"759154","DOI":"10.3389\/fcell.2021.759154","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Hao, R., Guo, Q., Zhang, S. & Wang, X. TP53 mutation infers a poor prognosis and is correlated to immunocytes infiltration in breast cancer. Front. Cell. Dev. Biol. 9, 759154 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"95834_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","volume":"196","author":"K Reinhardt","year":"2022","unstructured":"Reinhardt, K. et al. PIK3CA-mutations in breast cancer. Breast Cancer Res. Treat. 196, 483\u2013493 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"95834_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2020.08.003","volume":"38","author":"A Arruabarrena-Aristorena","year":"2020","unstructured":"Arruabarrena-Aristorena, A. et al. FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer. Cancer Cell. 38, 534\u2013550e539 (2020).","journal-title":"Cancer Cell."},{"key":"95834_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-024-01936-1","volume":"10","author":"N Liu","year":"2024","unstructured":"Liu, N. et al. FOXA1 and FOXA2: The regulatory mechanisms and therapeutic implications in cancer. Cell. Death Discov. 10, 172 (2024).","journal-title":"Cell. Death Discov"},{"key":"95834_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","volume":"52","author":"G Xu","year":"2020","unstructured":"Xu, G. et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat. Genet. 52, 198\u2013207 (2020).","journal-title":"Nat. Genet."},{"key":"95834_CR45","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/s41467-022-31780-9","volume":"13","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nat. Commun. 13, 4264 (2022).","journal-title":"Nat. Commun."},{"key":"95834_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3892\/ijo.2014.2377","volume":"44","author":"A Nakanishi","year":"2014","unstructured":"Nakanishi, A., Kitagishi, Y., Ogura, Y. & Matsuda, S. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review). Int. J. Oncol. 44, 1813\u20131819 (2014).","journal-title":"Int. J. Oncol."},{"key":"95834_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5937\/BII2202105T","volume":"13","author":"N Tanic","year":"2022","unstructured":"Tanic, N. et al. The impact of TP53 and PTEN tumor suppressor genes on response to different breast cancer treatment modalities. \u0411\u0438\u043e\u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0430 \u0418\u0441\u0442\u0440\u0430\u0436\u0438\u0432\u0430\u045a\u0430. 13, 105\u2013117 (2022).","journal-title":"\u0411\u0438\u043e\u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0430 \u0418\u0441\u0442\u0440\u0430\u0436\u0438\u0432\u0430\u045a\u0430"},{"key":"95834_CR48","doi-asserted-by":"publisher","first-page":"12188","DOI":"10.1074\/jbc.RA119.010710","volume":"295","author":"M Gasparyan","year":"2020","unstructured":"Gasparyan, M., Lo, M. C., Jiang, H., Lin, C. C. & Sun, D. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. J. Biol. Chem. 295, 12188\u201312202 (2020).","journal-title":"J. Biol. Chem."},{"key":"95834_CR49","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/onc.2014.4","volume":"34","author":"G Kim","year":"2015","unstructured":"Kim, G. et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene 34, 671\u2013680 (2015).","journal-title":"Oncogene"},{"key":"95834_CR50","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1541-7786.MCR-19-1108","volume":"18","author":"S Park","year":"2020","unstructured":"Park, S. et al. Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. Mol. Cancer Res. 18, 1315\u20131325 (2020).","journal-title":"Mol. Cancer Res."},{"key":"95834_CR51","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s42003-020-01301-9","volume":"3","author":"Y Inagaki-Kawata","year":"2020","unstructured":"Inagaki-Kawata, Y. et al. Genetic and clinical landscape of breast cancers with germline BRCA1\/2 variants. Commun. Biol. 3, 578 (2020).","journal-title":"Commun. Biol."},{"key":"95834_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/2159-8290.CD-11-0325","volume":"2","author":"FC Martins","year":"2012","unstructured":"Martins, F. C. et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2, 503\u2013511 (2012).","journal-title":"Cancer Discov"},{"key":"95834_CR53","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-21-2572","volume":"28","author":"AG Waks","year":"2022","unstructured":"Waks, A. G. et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin. Cancer Res. 28, 2339\u20132348 (2022).","journal-title":"Clin. Cancer Res."},{"key":"95834_CR54","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5858\/134.6.907","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of Estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 134, 907\u2013922 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"95834_CR55","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch, A. et al. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 22, 1736\u20131747 (2011).","journal-title":"Ann. Oncol."},{"key":"95834_CR56","doi-asserted-by":"publisher","first-page":"806","DOI":"10.5858\/arpa.2015-0133-RA","volume":"140","author":"P Tang","year":"2016","unstructured":"Tang, P. & Tse, G. M. Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update. Arch. Pathol. Lab. Med. 140, 806\u2013814 (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"95834_CR57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"95834_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41436-019-0686-8","volume":"22","author":"ER Riggs","year":"2020","unstructured":"Riggs, E. R. et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: A joint consensus recommendation of the American college of medical genetics and genomics (ACMG) and the clinical genome resource (ClinGen). Genet. Med. 22, 245\u2013257 (2020).","journal-title":"Genet. Med."},{"key":"95834_CR59","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone Receptor\u2013Positive advanced breast cancer. N Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N Engl. J. Med."},{"key":"95834_CR60","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95834-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:41:10Z","timestamp":1743842470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95834-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95834"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95834-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11427"}}